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Background:  While federal regulations require gradual dose reduction trials of antipsychotics 
prescribed for behavior management in nursing home (NH) residents with dementia, widespread 
concern about precipitating behavioral disturbances limits implementation.  We conducted a systematic 
review of clinical trials reducing antipsychotic drug use in NH residents to determine best dose reduction 
practices and risk of behavior escalation. 
 
Methods:  A comprehensive literature search was conducted in MEDLINE, EMBASE, and International 
Pharmaceutical Abstracts between January 1970 and October 2011 using the terms “antipsychotic agent 
or neuroleptic agent,” “dementia,” “nursing homes,” and “withdrawal.”  One investigator reviewed 
abstracts for inclusion based on: English-language, human subjects, clinical trial, nursing home site, and 
≥5 participants, and reported reduction in medications due to an intervention. We excluded review 
articles and commentaries and secondary analysis of main trial results. The remaining articles were 
reviewed by 2 investigators for final inclusion, resulting in 9 articles.  
 
Results:  The nine articles meeting inclusion criteria included randomized controlled trials of both typical 
and atypical antipsychotics. Study populations ranged in size from 55 to 183 NH residents with dementia 
and typically targeted patients who were not psychotic and did not have a history of violent behavior. 
Gradual dose reduction protocols typically followed a strategy of 50% dose reduction per week for 2-3 
sequential weeks. Outcomes measured included behavioral problems, cognitive function, and 
resumption of antipsychotic medications.  All 9 studies reported that the majority of residents 
randomized to gradual dose reductions of antipsychotics had no overall detrimental effect on functional 
and cognitive status, or exacerbation of behavioral symptoms.  
 
Conclusions:  Clinical trials evaluating the withdrawal of antipsychotic medications from NH residents 
with dementia do not show evidence of rebound behavioral escalation after gradual dose reductions.  
  
